Clinical Trial Update: Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients [Phase 2]

View source ↗

Summary

Phase 2 trial results on BFH772 for erythematotelangiectatic rosacea assessing safety, tolerability, and efficacy have completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erythematotelangiectatic Rosacea

Drugs mentioned

• BFH772

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Erythemato-telangiectatic Rosacea | Phase 2 | Status: COMPLETED